R(
Therapeutic Areas
Unity Biotechnology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| UBX1325 (foselutoclax) | Diabetic Macular Edema (DME) | Phase 2b |
| UBX0101 | Osteoarthritis of the Knee | Phase 2 |
| UBX1967 | Ophthalmology (Undisclosed) | Preclinical |
| CNS Programs | Undisclosed Neurological Diseases | Discovery/Preclinical |
Leadership Team at Unity Biotechnology
AG
Anirvan Ghosh
Chief Executive Officer
JD
Jamie Dananberg
Chief Medical Officer
MP
Michael P. Samar
Chief Development Officer
DL
David L. Lacey
Strategic Advisor, Former Interim CEO
KC
Keith C. Leonard, Jr.
Chairman of the Board of Directors
NH
Natalie Holles
Director
A(
Alexander (Sandy) R. Thessin
Director
JC
Judith Campisi
Co-founder, Scientific Advisory Board
JV
Jan van Deursen
Co-founder
N"
Nathaniel "Ned" David
Co-founder, former President & CSO